Jeffrey S Borer

Summary

Publications

  1. doi request reprint Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)
    Jeffrey S Borer
    Division of Cardiovascular Medicine, The Howard Gilman Institute for Heart Valve Disease and the Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center, New York, New York Electronic address
    Am J Cardiol 113:497-503. 2014
  2. pmc Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
    Jeffrey S Borer
    Department of Medicine, State University of New York Downstate Medical Center, Brooklyn and New York, NY 10128 1152, USA
    Eur Heart J 33:2813-20. 2012
  3. ncbi request reprint Therapeutic effects of I(f) blockade: evidence and perspective
    Jeffrey S Borer
    The Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, The New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA
    Pharmacol Res 53:440-5. 2006
  4. ncbi request reprint Valves in the heart of the Big Apple V
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Expert Rev Cardiovasc Ther 5:621-3. 2007
  5. ncbi request reprint Clinical effect of 'pure' heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10128 1152, USA
    Adv Cardiol 43:54-64. 2006
  6. pmc Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases at Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Res Ther 7:S14-22. 2005
  7. doi request reprint Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor
    Jeffrey S Borer
    Cardiovascular Pathophysiology Unit and The Howard Gilman Institute for Valvular Heart Diseases, Weill Cornell Medical College, New York, NY 10128 1152, USA
    Am J Ther 15:461-73. 2008
  8. ncbi request reprint Cyclooxygenase inhibition: what should we do to resolve the confusion? An American perspective
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, and The New York Presbyterian Hospital Weill Cornell Medial Center, New York, NY 10021, USA
    J Cardiovasc Pharmacol 47:S87-91. 2006
  9. doi request reprint Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus
    Jeffrey S Borer
    Howard Gilman Institute for Heart Valve Diseases, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Am J Cardiol 105:29-35. 2010
  10. ncbi request reprint Cellular and molecular basis of remodeling in valvular heart diseases
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Heart Fail Clin 2:415-24. 2006

Detail Information

Publications55

  1. doi request reprint Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study)
    Jeffrey S Borer
    Division of Cardiovascular Medicine, The Howard Gilman Institute for Heart Valve Disease and the Schiavone Institute for Cardiovascular Translational Research, State University of New York Downstate Medical Center, New York, New York Electronic address
    Am J Cardiol 113:497-503. 2014
    ..In conclusion, our analysis confirms that heart rate reduction with ivabradine can be safely used in severe HF and may improve clinical outcomes independently of disease severity...
  2. pmc Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
    Jeffrey S Borer
    Department of Medicine, State University of New York Downstate Medical Center, Brooklyn and New York, NY 10128 1152, USA
    Eur Heart J 33:2813-20. 2012
    ..We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial...
  3. ncbi request reprint Therapeutic effects of I(f) blockade: evidence and perspective
    Jeffrey S Borer
    The Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, The New York Presbyterian Hospital, Weill Cornell Medical Center, New York, NY, USA
    Pharmacol Res 53:440-5. 2006
    ..The data supporting the use of the drug for angina prevention, and the potential for additional applications, are reviewed in this article...
  4. ncbi request reprint Valves in the heart of the Big Apple V
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    Expert Rev Cardiovasc Ther 5:621-3. 2007
  5. ncbi request reprint Clinical effect of 'pure' heart rate slowing with a prototype If current inhibitor: placebo-controlled experience with ivabradine
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10128 1152, USA
    Adv Cardiol 43:54-64. 2006
    ..Additional studies now must assess other potential actions in patients with coronary disease...
  6. pmc Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases at Weill Medical College of Cornell University, New York, New York, USA
    Arthritis Res Ther 7:S14-22. 2005
    ....
  7. doi request reprint Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor
    Jeffrey S Borer
    Cardiovascular Pathophysiology Unit and The Howard Gilman Institute for Valvular Heart Diseases, Weill Cornell Medical College, New York, NY 10128 1152, USA
    Am J Ther 15:461-73. 2008
    ..They also suggest that management of treatment should be relatively simple in most patients...
  8. ncbi request reprint Cyclooxygenase inhibition: what should we do to resolve the confusion? An American perspective
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, and The New York Presbyterian Hospital Weill Cornell Medial Center, New York, NY 10021, USA
    J Cardiovasc Pharmacol 47:S87-91. 2006
    ..This article explores the goals and possible designs of trials appropriate for defining risk-benefit relationship that must be known for optimal application of NSAID therapy...
  9. doi request reprint Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus
    Jeffrey S Borer
    Howard Gilman Institute for Heart Valve Diseases, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Am J Cardiol 105:29-35. 2010
    ..Ivabradine represents an attractive alternative to beta blockers in patients with stable angina pectoris and DM...
  10. ncbi request reprint Cellular and molecular basis of remodeling in valvular heart diseases
    Jeffrey S Borer
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Heart Fail Clin 2:415-24. 2006
  11. ncbi request reprint Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial
    Jeffrey S Borer
    Weill Medical College of Cornell University, New York, NY, USA
    Circulation 107:817-23. 2003
    ..This study evaluated the antianginal and antiischemic effects of ivabradine, a new heart rate-lowering agent that acts specifically on the sinoatrial node...
  12. doi request reprint Usefulness of preoperative exercise tolerance to predict late survival and symptom persistence after surgery for chronic nonischemic mitral regurgitation
    Phyllis G Supino
    The Howard Gilman Institute for Valvular Heart Diseases, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Am J Cardiol 111:1625-30. 2013
    ..Future research should determine whether interventions to improve exercise tolerance before mitral valve surgery can modify these postoperative outcomes...
  13. doi request reprint Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts
    Sharada L Truter
    The Division of Cardiovascular Medicine and The Howard Gilman Institute for Heart Valve Disease, State University of New York Downstate Medical Center, 47 East 88th Street, New York, NY 10128, USA
    Cardiology 113:161-8. 2009
    ..Myocardial fibrosis in experimental aortic regurgitation (AR) features abnormal fibronectin with normal collagen content, but the relevant degradative processes have not been assessed...
  14. ncbi request reprint The cellular and molecular basis of heart failure in regurgitant valvular diseases: the myocardial extracellular matrix as a building block for future therapy
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Department of Cardiothoracic Surgery and Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, N Y, USA
    Adv Cardiol 39:7-14. 2002
  15. ncbi request reprint Prognostic impact of systolic hypertension on asymptomatic patients with chronic severe aortic regurgitation and initially normal left ventricular performance at rest
    Phyllis G Supino
    Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, New York, USA
    Am J Cardiol 96:964-70. 2005
    ..The theoretically based practice of giving antihypertensive drugs to patients who have AR requires reexamination...
  16. ncbi request reprint Cellular response of human cardiac fibroblasts to mechanically simulated aortic regurgitation
    Anuj Gupta
    Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, New York Presbyterian Hospital Weill Cornell Medical Center, New York, New York 10021, USA
    Am J Ther 13:8-11. 2006
    ..These results simulate those found experimentally and suggest that human CF, like rabbit CF, manifest abnormal compositional distribution of ECM proteins in AR...
  17. ncbi request reprint Aortic regurgitation: selection of asymptomatic patients for valve surgery
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Department of Cardiothoracic Surgery, Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, N Y, USA
    Adv Cardiol 39:74-85. 2002
  18. ncbi request reprint Importance of right ventricular performance measurement in selecting asymptomatic patients with mitral regurgitation for valve surgery
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Department of Cardiothoracic Surgery, Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, N Y, USA
    Adv Cardiol 39:144-52. 2002
  19. ncbi request reprint Vesnarinone-mediated alterations of gene expression in cardiac fibroblasts from aortic regurgitant hearts
    Sharada L Truter
    Division of Cardiovascular Pathophysiology, Weill Medical College of Cornell University, New York, NY 10021, USA
    Am J Ther 11:328-36. 2004
    ..These pharmacologic effects may underlie potentially therapeutic mitigation of fibrosis by vesnarinone...
  20. ncbi request reprint Ventricular arrhythmias in mitral regurgitation: frequency, clinical and prognostic importance, management before and after mitral valve surgery
    Clare Hochreiter
    Division of Cardiovascular Pathophysiology, Department of Cardiothoracic Surgery and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Adv Cardiol 41:108-11. 2004
  21. pmc Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation
    Phyllis G Supino
    Department of Medicine, Weill Cornell Medical College, New York, NY, USA
    Am J Cardiol 100:1274-81. 2007
    ..However, those with excellent exercise tolerance have a relatively benign course. Exercise-inducible ST-segment depression has no prognostic value in this population...
  22. pmc Nonischemic mitral regurgitation: prognostic value of nonsustained ventricular tachycardia after mitral valve surgery
    Oladipupo Olafiranye
    Division of Cardiovascular Medicine, Department of Medicine, The Howard Gilman Institute for Heart Valve Disease, State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Cardiology 124:108-15. 2013
    ..The prognostic value of VT after mitral valve surgery (MVS) is unknown; we aimed to define this prognostic value and to assess its modulation by left (LV) and/or right (RV) ventricular ejection fraction (EF) for mortality after MVS...
  23. ncbi request reprint Drug insight: If inhibitors as specific heart-rate-reducing agents
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York Presbyterian Hospital Weill Cornell Center, New York, NY 10021, USA
    Nat Clin Pract Cardiovasc Med 1:103-9. 2004
    ..No serious adverse events have been attributed to the treatment; the most prominent side-effect is dose-related, always reversible and often transient visual symptoms that seldom result in voluntary drug discontinuation...
  24. ncbi request reprint Valve surgery in the asymptomatic patient with aortic regurgitation: current indications and the effect of change rates in objective measures
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Department of Cardiothoracic Surgery, and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Adv Cardiol 41:36-47. 2004
  25. ncbi request reprint Heart failure in aortic regurgitation: the role of primary fibrosis and its cellular and molecular pathophysiology
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Adv Cardiol 41:16-24. 2004
  26. ncbi request reprint Left ventricular ejection fraction change with exercise versus ejection fraction at rest in coronary artery disease: implications for using ejection fraction variations in making therapeutic decisions
    Phyllis G Supino
    Division of Cardiovascular Pathophysiology, Weill Medical College of Cornell University, New York, NY, USA
    Am J Ther 11:164-70. 2004
    ..Further study is needed to determine whether LVEFrest should be used in selecting exercise-based prognostic descriptors in individual patients...
  27. ncbi request reprint The epidemiology of valvular heart diseases: the problem is growing
    Phyllis G Supino
    Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
    Adv Cardiol 41:9-15. 2004
  28. doi request reprint Acceptability and psychometric properties of the Minnesota Living With Heart Failure Questionnaire among patients undergoing heart valve surgery: validation and comparison with SF-36
    Phyllis G Supino
    The Howard Gilman Institute for Valvular Heart Diseases, Weill Cornell Medical College, New York, NY 11203, USA
    J Card Fail 15:267-77. 2009
    ..Disease-specific instruments have been used in heart failure (HF), commonly associated with valve disease, but have been neither validated nor routinely applied among patients undergoing VS...
  29. ncbi request reprint The epidemiology of valvular heart disease: a growing public health problem
    Phyllis G Supino
    Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NY 10021, USA
    Heart Fail Clin 2:379-93. 2006
  30. ncbi request reprint Contemporary approach to aortic and mitral regurgitation
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY, USA
    Circulation 108:2432-8. 2003
  31. ncbi request reprint Myocardial fibrosis in chronic aortic regurgitation: molecular and cellular responses to volume overload
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, The Howard Gilman Institute for Valvular Heart Diseases, Department of Anatomy and Cell Biology, Weill Medical College of Cornell University, New York, NY, USA
    Circulation 105:1837-42. 2002
    ..Myocardial fibrosis is common in patients with chronic aortic regurgitation (AR). Experimentally, fibrosis with disproportionate noncollagen extracellular matrix (ECM) elements precedes and contributes to heart failure in AR...
  32. ncbi request reprint Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology, Weill Medical College of Cornell University, 47 East 88th Street, New York, NY 10128 1152, USA
    Eur Heart J 28:1904-9. 2007
    ....
  33. ncbi request reprint Mitral regurgitation: natural history in operated and unoperated patients
    Clare A Hochreiter
    Division of Cardiovascular Pathophysiology, Department of Cardiothoracic Surgery, Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, N Y, USA
    Adv Cardiol 39:122-9. 2002
  34. ncbi request reprint Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib
    William B White
    Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Am J Cardiol 92:411-8. 2003
    ..These comparative analyses demonstrate no evidence of increased risk of cardiovascular thrombotic events associated with celecoxib compared with either conventional NSAIDs or placebo...
  35. ncbi request reprint The epidemiology of valvular heart disease: an emerging public health problem
    Phyllis G Supino
    Division of Cardiovascular Pathophysiology, Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, N Y, USA
    Adv Cardiol 39:1-6. 2002
  36. ncbi request reprint Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating nonregulator
    Jeffrey S Borer
    Division of Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
    J Am Coll Cardiol 44:2285-92. 2004
    ..This article will discuss and expand on these issues, with examples...
  37. ncbi request reprint Teaching clinical research methodology to the academic medical community: a fifteen-year retrospective of a comprehensive curriculum
    Phyllis G Supino
    Cardiovascular Pathophysiology and The Howard Gilman Institute for Valvular Heart Diseases, Weill Medical College of Cornell University, New York, NY, USA
    Med Teach 29:346-52. 2007
    ..Due to inadequate preparation, many medical professionals are unable to critically evaluate published research articles or properly design, execute and present their own research...
  38. ncbi request reprint The clinical development of percutaneous heart valve technology
    Thomas A Vassiliades
    J Thorac Cardiovasc Surg 129:970-6. 2005
  39. ncbi request reprint The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society of Cardiovascular Angiography and Intervention (SCAI)
    Thomas A Vassiliades
    Division of Cardiothoracic Surgery Emory University School of Medicine, 1365 Clifton Road NE, Atlanta, GA 30322, USA
    Catheter Cardiovasc Interv 65:73-9. 2005
  40. ncbi request reprint The funny current: cellular basis for the control of heart rate
    Dario DiFrancesco
    Department of Biomolecular Sciences and Biotechnology, Laboratory of Molecular Physiology and Neurobiology, University of Milan, Milan, Italy
    Drugs 67:15-24. 2007
    ..This short article reviews the current state of knowledge of the properties of the 'funny' current in relation to exploitation of the I(f) function in pacemaking generation and modulation for the pharmacological control of heart rate...
  41. ncbi request reprint If inhibition by Ivabradine. Foreword
    Jeffrey S Borer
    Drugs 67:1-2. 2007
  42. ncbi request reprint Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials
    William B White
    Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT, USA
    Am J Cardiol 99:91-8. 2007
    ..In conclusion, these analyses failed to demonstrate an increased CV risk with celecoxib relative to placebo and demonstrated a comparable rate of CV events with celecoxib treatment compared with nonselective NSAIDs...
  43. ncbi request reprint Resting heart rate in cardiovascular disease
    Kim Fox
    Royal Brompton Hospital, Sydney Street, London SW3 6NP, England
    J Am Coll Cardiol 50:823-30. 2007
    ..These findings suggest that the potential role of HR and its modulation should be considered in future cardiovascular guidance documents...
  44. ncbi request reprint The Editor's Roundtable: cardiac valve surgery
    Vincent E Friedewald
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Am J Cardiol 99:1269-78. 2007
  45. ncbi request reprint The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI)
    Thomas A Vassiliades
    Ann Thorac Surg 79:1812-8. 2005
  46. ncbi request reprint A new course on hypothesis and protocol development
    Phyllis G Supino
    Med Educ 41:525-6. 2007
  47. ncbi request reprint Equilibrium radionuclide angiocardiography
    James R Corbett
    J Nucl Cardiol 13:e56-79. 2006
  48. ncbi request reprint Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD
    Thomas Fleming
    Circulation 109:e9004-5. 2004
  49. ncbi request reprint Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
    Douglas L Mann
    Winters Center for Heart Failure Research, Baylor College of Medicine and the Houston VA, Houston, Tex 77030, USA
    Circulation 109:1594-602. 2004
    ..Studies in experimental models and preliminary clinical experience suggested a possible therapeutic role for the soluble tumor necrosis factor antagonist etanercept in heart failure...
  50. ncbi request reprint Aortic valve replacement for the asymptomatic patient with aortic regurgitation: a new piece of the strategic puzzle
    Jeffrey S Borer
    Circulation 106:2637-9. 2002
  51. ncbi request reprint Similarities and differences in design considerations for cell therapy and pharmacologic cardiovascular clinical trials
    Richard M Lewis
    Access BIO, Boyce, VA, USA
    Cardiology 110:73-80. 2008
    ..Efforts to discover innovative therapies must be balanced by a commitment to comprehensively evaluate the safety and efficacy of the new treatments...
  52. ncbi request reprint Left ventricular hypertrophy in hypertrophic cardiomyopathy: what's in a phenotype?
    Jeffrey S Borer
    J Am Coll Cardiol 44:406-8. 2004
  53. ncbi request reprint Aortic stenosis and statins: more evidence of "pleotropy"?
    Jeffrey S Borer
    Arterioscler Thromb Vasc Biol 25:476-7. 2005
  54. ncbi request reprint The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society for Cardiovascular Angiography and Interventions (SCAI)
    Thomas A Vassiliades
    Guidant
    J Am Coll Cardiol 45:1554-60. 2005